Skip to content
Menu
  • Home
  • About Us
  • Science & Technology
  • Pipeline
  • Investor Relations
  • Other Resources
  • Patient Resources
  • Contact

Author: Robbie Moore

Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease

Harnessing Regulatory T cell Neuroprotective Activities for Treatment of Neurodegenerative Disorders

Treg Enhancing Therapies to Treat Autoimmune Diseases

← older

We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. We are currently developing our multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Links

  • About Us
  • Science & Technology
  • Pipeline
  • Investor Relations
  • Other Resources
  • Patient Resources
  • About Us
  • Science & Technology
  • Pipeline
  • Investor Relations
  • Other Resources
  • Patient Resources

follow us

Linkedin Youtube Twitter

Contact Us

  • 5850 San Felipe St., Suite 500 Houston, TX 77057 USA
  • +1 800-587-8170
Contact Us
©2022 Coya Therapeutics, Inc. All rights reserved.
  • Privacy Policy
  • Terms & Conditions
Compnay-logo

Biotech Website Design